Prophylactic Aspirin Dose and Preeclampsia

dc.contributor.authorKupka, Ellen
dc.contributor.authorHesselman, Susanne
dc.contributor.authorGunnarsdóttir, Jóhanna
dc.contributor.authorWikström, Anna Karin
dc.contributor.authorCluver, Catherine
dc.contributor.authorTong, Stephen
dc.contributor.authorHastie, Roxanne
dc.contributor.authorBergman, Lina
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2026-01-08T09:48:01Z
dc.date.available2026-01-08T09:48:01Z
dc.date.issued2025
dc.descriptionPublisher Copyright: © 2025 American Medical Association. All rights reserved.en
dc.description.abstractImportance: It is unclear whether a higher dose (150-160 mg) or a lower dose (75 mg) of aspirin should be used to prevent preeclampsia. Objectives: To compare the risk of preeclampsia and bleeding complications between women using 150 to 160 mg of aspirin and those using 75 mg of aspirin for preeclampsia prevention. Design, Setting, and Participants: This nationwide cohort study included 13828 women giving birth at 22 weeks' gestation or later in Sweden between January 2017 and December 2020 who used low dose aspirin (75-160 mg) during pregnancy. Data were analyzed from October to November 2023. Exposure: The use of 150 to 160 mg or 75 mg of aspirin in pregnancy. Main Outcome and Measures: The main outcome was a preeclampsia diagnosis recorded in the maternal birth record at the time of hospital discharge. The main safety outcome was postpartum hemorrhage, defined as bleeding more than 1000 mL after delivery. Relative risks (RRs) and 95% CIs were estimated using a doubly robust inverse probability-weighted regression adjustment model controlling for background characteristics. Results: In the total cohort of 13828 women, the mean (SD) age was 33.0 (5.5) years and 3003 women (21.7%) were nulliparous. Of the women, 4687 (33.9%) were prescribed 150 to 160 mg of aspirin, and 9141 (66.1%) were prescribed 75 mg of aspirin. A total of 10635 women (76.9%) had at least 2 dispensed prescriptions of low-dose aspirin. Among women using 150 to 160 mg of aspirin, 443 (9.5%) developed preeclampsia compared with 812 (8.9%) of those using 75 mg of aspirin (adjusted RR [aRR], 1.07; 95% CI, 0.93-1.24). Additionally, the risk of postpartum hemorrhage between the groups was similar, with 326 women (6.9%) using 150 to 160 mg of aspirin experiencing a postpartum hemorrhage compared with 581 (6.4%) in the 75-mg group (aRR, 1.08; 95% CI, 0.90-1.30). Conclusions and Relevance: In this cohort study of 13828 women, no difference was found in preeclampsia incidence or bleeding complications between those using 150 to 160 mg of aspirin vs 75 mg of aspirin during pregnancy for preeclampsia prevention. These findings suggest that either dose may be a reasonable choice when using aspirin to prevent preeclampsia. However, large randomized trials investigating aspirin dose in pregnancy are still needed.en
dc.description.versionPeer revieweden
dc.format.extent848775
dc.format.extente2457828
dc.identifier.citationKupka, E, Hesselman, S, Gunnarsdóttir, J, Wikström, A K, Cluver, C, Tong, S, Hastie, R & Bergman, L 2025, 'Prophylactic Aspirin Dose and Preeclampsia', JAMA network open, vol. 8, no. 2, e2457828, pp. e2457828. https://doi.org/10.1001/jamanetworkopen.2024.57828en
dc.identifier.doi10.1001/jamanetworkopen.2024.57828
dc.identifier.issn2574-3805
dc.identifier.other236535448
dc.identifier.other41ee5115-b0bc-4317-83b9-b6156a41ae02
dc.identifier.other85217880830
dc.identifier.other39899294
dc.identifier.otherunpaywall: 10.1001/jamanetworkopen.2024.57828
dc.identifier.urihttps://hdl.handle.net/20.500.11815/7994
dc.language.isoen
dc.relation.ispartofseriesJAMA network open; 8(2)en
dc.relation.urlhttps://www.scopus.com/pages/publications/85217880830en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectHumansen
dc.subjectPre-Eclampsia/prevention & controlen
dc.subjectAspirin/administration & dosageen
dc.subjectFemaleen
dc.subjectPregnancyen
dc.subjectAdulten
dc.subjectSweden/epidemiologyen
dc.subjectCohort Studiesen
dc.subjectDose-Response Relationship, Drugen
dc.subjectPostpartum Hemorrhage/prevention & controlen
dc.subjectPlatelet Aggregation Inhibitors/administration & dosageen
dc.subjectGeneral Medicineen
dc.titleProphylactic Aspirin Dose and Preeclampsiaen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
kupka_2025_oi_241616_1738185891.57767.pdf
Stærð:
828.88 KB
Snið:
Adobe Portable Document Format

Undirflokkur